TIDMALK TIDMB

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Søren Jelert, Executive Vice President, CFO and member of the Board of Management, has decided to resign his position to join a company in another sector and will expectedly leave ALK on 31 May 2023.

Chairman of the Board of Directors, Anders Hedegaard, and President & CEO, Carsten Hellmann said: "We would like to offer our sincere thanks to Søren for his pivotal role in ALK's transformation over the past five years. We wish him the best of luck in his future career."

A search for a new CFO has been initiated.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, mobile +45 3050 2014

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

   -- FM_18_22UK_30112022 
      https://ml-eu.globenewswire.com/Resource/Download/b58450aa-fe21-4abf-bdb0-3ec56cc4b78f

(END) Dow Jones Newswires

November 30, 2022 11:24 ET (16:24 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alkemy Capital Investments Charts.
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alkemy Capital Investments Charts.